Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

This study tests a drug called trilaciclib combined with standard chemoradiation and immunotherapy for people with locally advanced esophageal squamous cell carcinoma (cancer of the food pipe). Trilaciclib is designed to protect the bone marrow from being damaged during chemotherapy and radiation, potentially reducing serious side effects like low blood counts. **You may be eligible if:** - You are 18 or older with histologically confirmed locally advanced esophageal squamous cell carcinoma - Your cancer is at stage II-IV and is not suitable for surgery, or you have refused surgery - You have at least one measurable tumor - You have not received any prior systemic anti-cancer therapy (chemotherapy, radiation, immunotherapy, targeted therapy) **You may NOT be eligible if:** - You have already received any systemic cancer treatment (chemotherapy, immunotherapy, radiation, etc.) - You have distant organ metastases (cancer spread to organs like the liver or lungs) - Your general health is too poor to tolerate treatment - You do not have measurable disease Talk to your doctor to see if this trial is right for you.